GLP-1 receptor agonists: European drug regulator asks makers for evidence of self-harm
Abstract
GLP-1 receptor agonists: European drug regulator asks makers for evidence of
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Regulatory agencies have yet to reach definitive conclusions on the potential risk of suicidality among GLP-1 receptor agonist users owing to limitations in available evidence.
“Despite these efforts, regulatory agencies have yet to reach definitive conclusions owing to limitations in the available evidence.4 5”
From Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study (2025) · cites this paper as [5]
Cited by
Sorted by citations
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116 · see citing works
Shapiro, S. B., Yin, H., Yu, O. H. Y., Rej, S., Suissa, S., & Azoulay, L. (2025) · BMJ · doi:10.1136/bmj-2024-080679 · Cited by 49 · see citing works
- Authors
- Cohen, D.
- Corresponding author
- Cohen, Deborah
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2023-12-08
- Volume
- 383
- Pages
- p2906
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W4389489290
- Cited by
- 15
- References
- 0
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 4
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
- Locations
- BMJ (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, drug safety, self-harm, suicidal ideation, adverse drug reactions, European Medicines Agency, regulatory risk assessment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Self-Injurious Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
